Joint Publications with Residents

Research Mentor shown in bold. Resident(s) shown in color.
  1. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May 31. View in PubMed
  2. Kratz JR, Woodard G, Jablons DM. Management of Lung Cancer Invading the Superior Sulcus. Thorac Surg Clin. 2017 May; 27(2):149-157. View in PubMed
  3. Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget. 2016 Dec 06; 7(49):80415-80425. View in PubMed
  4. Kang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid. Sci Rep. 2016 Sep 28; 6:34022. View in PubMed
  5. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847. View in PubMed
  6. Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer. PLoS One. 2016; 11(2):e0148911. View in PubMed
  7. Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 2016 Feb 16; 7(7):8321-31. View in PubMed
  8. Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treat Res. 2016; 170:47-75. View in PubMed
  9. Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLoS One. 2015; 10(7):e0132134. View in PubMed
  10. Hirata T, Zheng Q, Chen Z, Kinoshita H, Okamoto J, Kratz J, Li H, Lui N, Do H, Cheng T, Tseng HH, Koizumi K, Shimizu K, Zhou HM, Jablons D, He B. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma. Oncol Rep. 2015 Apr; 33(4):2052-60. View in PubMed
  11. Woodard GA, Jablons DM. The Latest in Surgical Management of Stage IIIA Non-Small Cell Lung Cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling. Am Soc Clin Oncol Educ Book. 2015; e435-41. View in PubMed
  12. Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 2014 Dec 15; 20(24):6551-8. View in PubMed
  13. Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov; 15(6):426-32. View in PubMed
  14. Kratz JR, Mann MJ, Jablons DM. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature. Transl Lung Cancer Res. 2013 Jun; 2(3):222-5. View in PubMed
  15. Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, Hurst JW, Segal MR, Berryman DM, Chu W, He B, Jablons DM, Mann MJ. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol. 2013 Jun; 22(2):65-9. View in PubMed
  16. Bosco-Clément G, Zhang F, Chen Z, Zhou HM, Li H, Mikami I, Hirata T, Yagui-Beltran A, Lui N, Do HT, Cheng T, Tseng HH, Choi H, Fang LT, Kim IJ, Yue D, Wang C, Zheng Q, Fujii N, Mann M, Jablons DM, He B. Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene. 2014 Apr 17; 33(16):2087-97. View in PubMed
  17. Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B. Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS One. 2013; 8(3):e57346. View in PubMed
  18. Mann MJ, Jablons DM, Kratz JR. Prognostic assay in small, node-negative non-small cell lung cancer--reply. JAMA. 2013 Feb 27; 309(8):769-70. View in PubMed
  19. Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013 Feb 05; 32:7. View in PubMed
  20. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun. 2013; 4:1701. View in PubMed
  21. Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. BMJ Open. 2012; 2(6). View in PubMed
  22. Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B. The role of stem cells in airway repair: implications for the origins of lung cancer. Chin J Cancer. 2013 Feb; 32(2):71-4. View in PubMed
  23. Kratz JR, Van den Eeden SK, He J, Jablons DM, Mann MJ. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012 Oct 24; 308(16):1629-31. View in PubMed
  24. Kim JW, Lee S, Lui N, Choi H, Mulvihill M, Fang LT, Kang HC, Kwon YW, Jablons D, Kim IJ. A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. Oncol Rep. 2012 Oct; 28(4):1225-30. View in PubMed
  25. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 03; 379(9818):823-32. View in PubMed
  26. Okamoto J, Kratz JR, Hirata T, Mikami I, Raz D, Segal M, Chen Z, Zhou HM, Pham P, Li H, Yagui-Beltran A, Beltran A, Ray MR, Koizumi K, Shimizu K, Jablons D, He B. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients. Clin Lung Cancer. 2011 Jul; 12(4):237-44. View in PubMed
  27. Kratz JR, Yagui-Beltrán A, Jablons DM. Cancer stem cells in lung tumorigenesis. Ann Thorac Surg. 2010 Jun; 89(6):S2090-5. View in PubMed
  28. Kratz JR, Jablons DM. Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer. 2009 May; 10(3):151-7. View in PubMed
  29. Raz DJ, Gomez SL, Chang ET, Kim JY, Keegan TH, Pham J, Kukreja J, Hiatt RA, Jablons DM. Epidemiology of non-small cell lung cancer in Asian Americans: incidence patterns among six subgroups by nativity. J Thorac Oncol. 2008 Dec; 3(12):1391-7. View in PubMed
  30. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 2008 Sep 01; 14(17):5565-70. View in PubMed
  31. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J, Rosell R. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res. 2008 Aug 01; 14(15):4794-9. View in PubMed
  32. Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008 Jul; 30(7):946-63. View in PubMed
  33. Kim J, Raz D, Jablons D. Unmet need in lung cancer: can vaccines bridge the gap? Clin Lung Cancer. 2008 Feb; 9 Suppl 1:S6-12. View in PubMed
  34. Brouchet L, Bauvin E, Marcheix B, Bigay-Game L, Renaud C, Berjaud J, Falcoze PE, Venissac N, Raz D, Jablons D, Mazières J, Dahan M. Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer. J Thorac Oncol. 2007 Jul; 2(7):626-31. View in PubMed
  35. Raz DJ, Kim JY, Jablons DM. Diagnosis and treatment of bronchioloalveolar carcinoma. Curr Opin Pulm Med. 2007 Jul; 13(4):290-6. View in PubMed
  36. Raz DJ, Jablons DM. EGFR expression and mutational analysis as a predictive test. J Clin Oncol. 2007 May 20; 25(15):2144; author reply 2144-5. View in PubMed
  37. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007 Jul; 132(1):193-9. View in PubMed
  38. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer. 2007 Apr 15; 109(8):1454-61. View in PubMed
  39. Raz DJ, Jablons DM. Five-gene signature in non-small-cell lung cancer. N Engl J Med. 2007 Apr 12; 356(15):1582; author reply 1583. View in PubMed
  40. Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B, Jablons D. Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg. 2007 Mar; 133(3):733-7. View in PubMed
  41. Raz DJ, Glidden DV, Odisho AY, Jablons DM. Clinical characteristics and survival of patients with surgically resected, incidentally detected lung cancer. J Thorac Oncol. 2007 Feb; 2(2):125-30. View in PubMed
  42. Kim JY, Harvard C, You L, Xu Z, Kuchenbecker K, Baehner R, Jablons D. Stathmin is overexpressed in malignant mesothelioma. Anticancer Res. 2007 Jan-Feb; 27(1A):39-44. View in PubMed
  43. Raz DJ, Odisho AY, Franc BL, Jablons DM. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg. 2006 Nov; 132(5):1189-95. View in PubMed
  44. Raz DJ, Zell JA, Karnezis AN, Odisho A, Ignatius Ou SH, Anton-Culver H, Jablons DM. Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer. J Thorac Oncol. 2006 Nov; 1(9):943-8. View in PubMed
  45. Yagui-Beltrán A, He B, Raz D, Kim J, Jablons DM. Novel therapies targeting signaling pathways in lung cancer. Thorac Surg Clin. 2006 Nov; 16(4):379-96, vi. View in PubMed
  46. Raz DJ, He B, Rosell R, Jablons DM. Current concepts in bronchioloalveolar carcinoma biology. Clin Cancer Res. 2006 Jun 15; 12(12):3698-704. View in PubMed
  47. Raz DJ, Jablons DM. Bronchioloalveolar carcinoma is not associated with younger age at diagnosis: an analysis of the SEER database. J Thorac Oncol. 2006 May; 1(4):339-43. View in PubMed
  48. Raz DJ, He B, Rosell R, Jablons DM. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer. 2006 Mar; 7(5):313-22. View in PubMed
  49. Lin YC, You L, Xu Z, He B, Mikami I, Thung E, Chou J, Kuchenbecker K, Kim J, Raz D, Yang CT, Chen JK, Jablons DM. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun. 2006 Mar 10; 341(2):635-40. View in PubMed
  50. You L, Kim J, He B, Xu Z, McCormick F, Jablons DM. Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect. 2006 Jan-Feb; 19(1):27-31. View in PubMed
Data provided by UCSF Profiles, powered by CTSI at UCSF. View profile of David M. Jablons, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.